Pimavanserin: A Truly Effective Treatment for Parkinson’s Disease Psychosis? A Review of Interventions
Beatrice Heim, Marina Peball, Florian Krismer, Atbin Djamshidian, Klaus Seppi
Abstract
Parkinson's disease (PD) is the second-most common neurodegenerative disorder with a long-term 60% cumulative prevalence of PD psychosis. Medical treatment is limited to few atypical antipsychotic drugs with low affinity to dopamine D2 receptors. In 2016, pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved by the US Food and Drug Administration (FDA) as the only treatment for PD psychosis (PDP). This article provides an overview of the epidemiology, pathophysiology, and treatment options for PDP and illuminates the mode of action and therapy options with pimavanserin and the current study data.
Topics & Concepts
MedicinePsychosisAntipsychoticDiseaseParkinson's diseaseInverse agonistAtypical antipsychoticDopamine receptor D2Psychological interventionAgonistPsychiatrySchizophrenia (object-oriented programming)DopamineReceptorInternal medicineParkinson's Disease Mechanisms and TreatmentsBiotin and Related StudiesNeurotransmitter Receptor Influence on Behavior